SGX-523MET inibitor, highly selective, ATP-competitive CAS# 1022150-57-7 |
- PHA-665752
Catalog No.:BCC1181
CAS No.:477575-56-7
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
- Tivantinib (ARQ 197)
Catalog No.:BCC3688
CAS No.:905854-02-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1022150-57-7 | SDF | Download SDF |
PubChem ID | 24779724 | Appearance | Powder |
Formula | C18H13N7S | M.Wt | 359.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | SGX523,SGX 523 | ||
Solubility | DMSO : ≥ 3.6 mg/mL (10.02 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline | ||
SMILES | CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2 | ||
Standard InChIKey | BCZUAADEACICHN-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H13N7S/c1-24-11-13(10-20-24)16-6-7-17-21-22-18(25(17)23-16)26-14-4-5-15-12(9-14)3-2-8-19-15/h2-11H,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective c-MET kinase inhibitor (IC50 = 4nM). Exhibits minimal inhibition against a panel of 213 other protein kinases (at 1 μM). Suppresses growth of tumor xenografts derived from human glioblastoma, lung and gastric cancer cells. |
SGX-523 Dilution Calculator
SGX-523 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7823 mL | 13.9117 mL | 27.8234 mL | 55.6468 mL | 69.5584 mL |
5 mM | 0.5565 mL | 2.7823 mL | 5.5647 mL | 11.1294 mL | 13.9117 mL |
10 mM | 0.2782 mL | 1.3912 mL | 2.7823 mL | 5.5647 mL | 6.9558 mL |
50 mM | 0.0556 mL | 0.2782 mL | 0.5565 mL | 1.1129 mL | 1.3912 mL |
100 mM | 0.0278 mL | 0.1391 mL | 0.2782 mL | 0.5565 mL | 0.6956 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SGX-523 is a novel, potent, ATP-competitive, and highly-selective Hepatocyte growth factor receptor (MET) inhibitor with IC50 value of 4 nM [1].
SGX523 inhibits MET autophosphorylation in gastric cancer cell line GTL16 and human lung carcinoma cell line A549, with IC50 of 40 nM and 12 nM, respectively [1]. Additionally, tumor regression was observed in gastic cancer cell line GTL16 and human GBM cell line U87MG derived mouse xenograft models that are treated with SGX-523 by oral gavage [1].
SGX523 has been shown to inhibit the phosphorylateion of MEK, MAPK, AKT in brain cancer cell lines including U87, U373, DAOY, as well as glioma stem cells 1228. The inhibition of MEK in brain cancer cells and stem cells led to cell proliferation, G1/S cell cycle progression, cell migration, and cell invasion [2].
References:
[1] Buchanan SG1, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, Tang CM, Huser NH, Felce JD, Froning KJ, Peterman MC, Aubol BE, Gessert SF,Sauder JM, Schwinn KD, Russell M, Rooney IA, Adams J, Leon BC, Do TH, Blaney JM, Sprengeler PA, Thompson DA, Smyth L, Pelletier LA, Atwell S, Holme K,Wasserman SR, Emtage S, Burley SK, Reich SH. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther. 2009 Dec;8(12):3181-90.
[2] Guessous F1, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, Buchanan S, Abounader R.An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem. 2010 Jan;10(1):28-35.
- Btk inhibitor 1 R enantiomer
Catalog No.:BCC5125
CAS No.:1022150-12-4
- ARN2966
Catalog No.:BCC8074
CAS No.:102212-26-0
- Tyrosine kinase inhibitor
Catalog No.:BCC2020
CAS No.:1021950-26-4
- Boc-4-oxo-Pro-OMe
Catalog No.:BCC3436
CAS No.:102195-80-2
- 3-O-Methyltirotundin
Catalog No.:BCN5837
CAS No.:1021945-29-8
- ZM 39923 HCl
Catalog No.:BCC2203
CAS No.:1021868-92-7
- AGN 192403 hydrochloride
Catalog No.:BCC6924
CAS No.:1021868-90-5
- ARL 67156 trisodium salt
Catalog No.:BCC7004
CAS No.:1021868-83-6
- PPNDS
Catalog No.:BCC7015
CAS No.:1021868-77-8
- Boc-D-N-Me-Phe.DCHA
Catalog No.:BCC3347
CAS No.:102185-45-5
- Boc-Arg(Mts)-OH
Catalog No.:BCC3054
CAS No.:102185-38-6
- Boc-D-Pro-OSu
Catalog No.:BCC3438
CAS No.:102185-34-2
- Epoxyparvinolide
Catalog No.:BCN5838
CAS No.:102227-61-2
- (R)-Eriodictyol-8-C-beta-D-glucopyranoside
Catalog No.:BCN8028
CAS No.:1023271-51-3
- Cadensin D
Catalog No.:BCN7260
CAS No.:102349-35-9
- Naringin
Catalog No.:BCN6312
CAS No.:10236-47-2
- Negsehisandrin G
Catalog No.:BCN2674
CAS No.:1023744-69-5
- Glyburide
Catalog No.:BCC4784
CAS No.:10238-21-8
- AF-DX 116
Catalog No.:BCC6939
CAS No.:102394-31-0
- Jasplakinolide
Catalog No.:BCC7485
CAS No.:102396-24-7
- Fmoc-Phg-OH
Catalog No.:BCC3312
CAS No.:102410-65-1
- RN 1747
Catalog No.:BCC7769
CAS No.:1024448-59-6
- Kushenol N
Catalog No.:BCN2984
CAS No.:102490-65-3
- GK921
Catalog No.:BCC8057
CAS No.:1025015-40-0
Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications.[Pubmed:20421447]
Drug Metab Dispos. 2010 Aug;38(8):1277-85.
An investigation was conducted to follow up on the apparent species-dependent toxicity reported for 6-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)quinolin e (SGX523), a mesenchymal-epithelial transition factor (c-MET) inhibitor that entered clinical development for the treatment of solid tumors. Patients treated with SGX523 exhibited compromised renal function presumably resulting from crystal deposits in renal tubules. Our independent metabo'lite profiling of SGX523 indicates that a major NADPH-independent, late-eluting metabolite [6-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)quinoli n-2(1H)-one (M11)] was generated by monkey and human liver S-9, and to a lesser extent by rat S-9, whereas M11 was absent in dog S-9 incubations. We confirmed the identity of M11 as 2-quinolinone-SGX523. Experiments with various molybdenum hydroxylase inhibitors showed that aldehyde oxidase (AO), and not xanthine oxidase, metabolized SGX523 to M11 in monkey and human liver cytosol. In addition, the oxygen incorporated into M11 was derived from water rather than atmospheric oxygen, corroborating M11 formation via AO. After oral dosing in monkeys, metabolite profiling of plasma and urine showed that SGX523 was indeed metabolized to M11 and its N-demethyl analog (M8). In urine, M11 levels were approximately 70-fold greater than that of SGX523, and the solubility of M11 in urine was only 3% of that of SGX523. In summary, SGX523 is metabolized by AO in a species-specific manner to a markedly less-soluble metabolite, M11. We propose that M11 is likely involved in the observed obstructive nephropathy reported in clinical studies. Moreover, this study illustrates the need to conduct thorough metabolic evaluations early in drug development to select the most relevant nonclinical species for toxicological evaluation.
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.[Pubmed:20643778]
Cancer Res. 2010 Sep 1;70(17):6880-90.
The hepatocyte growth factor (HGF)-MET pathway supports several hallmark cancer traits, and it is frequently activated in a broad spectrum of human cancers (http://www.vai.org/met/). With the development of many cancer drugs targeting this pathway, there is a need for relevant in vivo model systems for preclinical evaluation of drug efficacy. Here, we show that production of the human HGF ligand in transgenic severe combined immunodeficient mice (hHGF(tg)-SCID mice) enhances the growth of many MET-expressing human carcinoma xenografts, including those derived from lung, breast, kidney, colon, stomach, and pancreas. In this model, the MET-specific small-molecule kinase inhibitor SGX523 partially inhibits the HGF-dependent growth of lung, breast, and pancreatic tumors. However, much greater growth suppression is achieved by combinatorial inhibition with the epidermal growth factor receptor (EGFR) kinase inhibitor erlotinib. Together, these results validate the hHGF(tg)-SCID mouse model for in vivo determination of MET sensitivity to drug inhibition. Our findings also indicate that simultaneously targeting the MET and EGFR pathways can provide synergistic inhibitory effects for the treatment of cancers in which both pathways are activated.
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.[Pubmed:19934279]
Mol Cancer Ther. 2009 Dec;8(12):3181-90.
The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics. Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers. In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated. Several classes of ATP-competitive inhibitor have been described, which inhibit MET but also other kinases. Here, we describe SGX523, a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L and is >1,000-fold selective versus the >200-fold selectivity of other protein kinases tested in biochemical assays. Crystallographic study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the selectivity. SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concentrations but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concentrations. SGX523 inhibition of MET in vivo was associated with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity. Our results show that SGX523 is the most selective inhibitor of MET catalytic activity described to date and is thus a useful tool to investigate the role of MET kinase in cancer without the confounding effects of promiscuous protein kinase inhibition.
Novel [1,2,4] Triazol [4,3-a] Pyridine Derivatives as Potential Selective c-Met Inhibitors with Improved Pharmacokinetic Properties.[Pubmed:27804848]
Anticancer Agents Med Chem. 2017;17(8):1102-1112.
AIMS: Total twenty-nine [1,2,4]triazolo[4,3-a]pyrazine derivatives were designed and synthesized. METHOD: The target compounds, especially 4aa, showed potent activity to inhibit c-Met both in an enzyme assay and a cellular assay. The comprehensive screening for the inhibition of 60 different kinases revealed that 4aa could selectively inhibit c-Met while had no effect on other kinases, indicating 4aa is an excellent c-Met selective inhibitor. RESULT: The flow cytometry studies found that 4aa had a similar behavior to the positive control SGX-523 in terms of causing the tumor cell apoptosis and blocking cell-cycle progression. More importantly, 4aa showed much better pharmacokinetic properties than SGX-523. Altogether, the findings suggested the target compounds may be potential anti-tumor drug candidates.